SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): April 16, 2004
OSCIENT PHARMACEUTICALS CORPORATION
(Exact name of registrant as specified in its charter)
| Massachusetts | 0-10824 | 04-2297484 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (I.R.S. Employer Identification Number) |
100 Beaver Street
Waltham, Massachusetts 02453
(Address of principal executive offices, including zip code)
(781) 398-2300
(Registrant’s telephone number, including area code)
Item 7. FINANCIAL STATEMENTS AND EXHIBITS.
This Current Report on Form 8-K/A is being filed to amend the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 10, 2004 to add the following required financial statements:
(a) GeneSoft Pharmaceuticals, Inc.’s audited balance sheet and statements of operations, stockholders’ equity (net capital deficiency) and cash flows for the fiscal year ended December 31, 2003, attached hereto as Exhibit 99.1.
(b) The pro forma financial statements required by Article 11 of Regulation S-X, attached hereto as Exhibit 99.2.
(c) Exhibits
| 23.1 | Consent of Ernst & Young LLP, Independent Auditors | |
| 99.1 | GeneSoft Pharmaceuticals, Inc.’s audited balance sheet and statements of operations, stockholders’ equity (net capital deficiency) and cash flows for the fiscal year ended December 31, 2003. | |
| 99.2 | Pro Forma Financial Statements. | |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| OSCIENT PHARMACEUTICALS CORPORATION | ||
| By: |
/s/ Steven M. Rauscher | |
| Name: |
Steven M. Rauscher | |
| Title: |
CEO and President | |
Date: April 16, 2004
3
EXHIBIT INDEX
| Exhibit Number |
Description | |
| 23.1 | Consent of Ernst & Young LLP, Independent Auditors | |
| 99.1 | GeneSoft Pharmaceuticals, Inc.’s audited balance sheet and statements of operations, stockholders’ equity (net capital deficiency) and cash flows for the fiscal year ended December 31, 2003. | |
| 99.2 | Pro Forma Financial Statements. | |
4